We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Events

08 Dec 2026 - 10 Dec 2026
25 Jan 2027 - 28 Jan 2027

Multimodal AI Improves Treatment Response Prediction in Lung Cancer

By HospiMedica International staff writers
Posted on 18 Sep 2026

Immunotherapy has transformed care for advanced non-small cell lung cancer (NSCLC), yet only a minority of patients achieve durable benefit. More...

Clinicians still struggle to predict who will respond, and treatment decisions often rely on PD-L1 despite well-recognized limitations. More precise, data-driven tools could help tailor therapy and reduce unnecessary toxicity and cost. New findings demonstrate that multimodal artificial intelligence (AI) can improve prediction of treatment response and survival in this setting.

The I3LUNG multimodal AI tool is an international effort to support decision-making for immunotherapy in metastatic NSCLC. Built to outperform standard clinical biomarkers, the technology uses routinely collected patient information to classify likely responders and estimate survival outcomes. The study describing this approach was published in Nature Medicine on September 13, 2026.

At the University of Chicago Medicine, investigators and international partners integrated clinical, imaging, pathology, and genomic data from patients with advanced NSCLC into a shared database and trained two families of predictive models. Area under the curve (AUC), a standard machine-learning metric of discriminative performance, was used to evaluate accuracy. One model using clinical and blood data reached an AUC of 0.77, while a model that added imaging and digital pathology achieved an AUC of 0.88.

The retrospective analysis encompassed 2,396 patients treated with immunotherapy across six centers in Italy, Germany, Greece, Israel, Spain, and the United States. The AI models consistently outperformed standard biomarkers used in current practice. In a reader study, 20 physicians (10 lung cancer experts and 10 non-experts) reviewed 100 real cases first without and then with AI support; performance improved from an AUC of 0.72 to 0.87, and inter-physician agreement rose from slight to moderate.

The project has now moved into a prospective phase, enrolling more than 2,000 patients across the same international centers. This next step focuses on treatment optimization and on evaluating not only model performance but also clinical usability, aligning the tool with real-world decision-making needs.

“I3LUNG establishes a new benchmark for AI in thoracic oncology. Decision support tools built even from routinely available clinical data can outperform the biomarkers we rely on today. For patients, this means fewer missed opportunities for treatment benefit. For community physicians, it means access to expert-level guidance at the point of care. For the field, it provides a rigorous, fair, and explainable framework — validated across diverse healthcare systems and populations — that can serve as a global platform for the next generation of precision immunotherapy,” said Marina Garassino, MD, Professor of Medicine at UChicago Medicine and senior author of the study.

Related Links
University of Chicago Medicine


Gold Member
12-Channel ECG
CM1200B
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Hypodermic Syringe
SurTract™ Safety Syringe
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Design-science framework integrating CML and LLM pipelines for supply chain risk evaluation. (Gupta I, Konduru H, Correa S, et al. A causal analytics approach for interpretable supply chain risk and supplier performance evaluation. Supply Chain Analytics, 2026. doi:10.1016/j.sca.2026.100248)

Causal AI Tool Withholds Ovarian Cancer Treatment Recommendations When Evidence Insufficient

Ovarian cancer treatment often requires individualized decisions, particularly when available patient data do not clearly favor one therapeutic approach. However, artificial intelligence (AI) systems may... Read more

Patient Care

view channel
Image: A view inside the custom virtual reality environment used in the study: a calm room with a teddy bear, soft colors and large windows looking out over the sea. (Image Credit: Walaa S. Abu Rukbah et al., Virginia Commonwealth University; CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/)

Virtual Reality Program May Reduce Anxiety Before Pediatric Surgery

Presurgery anxiety affects an estimated 50% to 75% of children undergoing surgery and can complicate anesthesia induction, increase postoperative pain, and prolong recovery. Sedation is often used to manage... Read more

Medical Imaging

view channel
Image Credit: Adobe Stock

Lung Ultrasound Predicts Progression of Interstitial Lung Abnormalities in Rheumatoid Arthritis

Interstitial lung abnormalities are a pulmonary concern in patients with rheumatoid arthritis, requiring monitoring to detect disease progression. However, tracking these changes often involves repeated... Read more

Point of Care

view channel
Image: Jessica Ramella-Roman, professor of biomedical engineering at Florida International University, holding the PPRIM (Portable Preterm Imaging) device designed to detect early signs of preterm labor risk. (Photo courtesy of Florida International University)

Handheld Imaging Device May Help Identify Preterm Birth Risk Earlier

Preterm birth, defined as delivery before 37 weeks of pregnancy, can lead to serious neonatal complications, including neurological, developmental, and respiratory problems. However, identifying pregnancies... Read more

Business

view channel
Image: Stryker has acquired ZuriMED, adding the FiberLocker System, a rotator cuff augmentation technology designed to strengthen repairs, to its Sports Medicine portfolio. (Photo courtesy of ZuriMED)

Stryker Completes Acquisition to Broaden Shoulder Surgery Offerings

Stryker (Portage, MI, USA) has completed its acquisition of ZuriMED (Zurich, Switzerland), a privately held developer of the FiberLocker System, expanding its Sports Medicine portfolio with a commercialized... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.